Start of myeloma therapy may be delayed for women, minoritiesJanuary 21, 2020Multiple MyelomaLymphoma & Plasma Cell Disorders
CAR T-cell therapy may worsen mental health in some patientsJanuary 21, 2020TransplantationLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
REGN1979 shows good activity in pretreated aggressive B-NHLJanuary 15, 2020DLBCLLymphoma & Plasma Cell Disorders
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomasJanuary 14, 2020Aggressive LymphomasPediatricsDLBCLLymphoma & Plasma Cell Disorders
CAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020ALLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCL
D-RVd for frontline myeloma looks robust in GRIFFIN trial updateDecember 17, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Some MCL patients can safely stop venetoclax-ibrutinib, study suggestsDecember 14, 2019Lymphoma & Plasma Cell Disorders
KTE-X19 produces highest response rate in MCL subgroupDecember 14, 2019Lymphoma & Plasma Cell Disorders
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCLDecember 12, 2019Lymphoma & Plasma Cell Disorders
Study halted; ‘hyperprogression’ seen with nivolumab for R/R PTCLDecember 9, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCLDecember 8, 2019DLBCLLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Myeloma patients over age 70 can benefit from auto-HC transplantDecember 7, 2019TransplantationMultiple MyelomaLymphoma & Plasma Cell Disorders
